User banner image
User avatar
  • admin

Posts

Global gathering honors Confucius’ legacy

QUFU, China, Sept. 28, 2024 /PRNewswire/ — A news report from chinadaily.com.cn: The 2024 China International Confucius Cultural Festival, which kicked off on Sept 27 in...

Global Times: Xi presides over top meeting to arrange for economic work

BEIJING, Sept. 28, 2024 /PRNewswire/ — The Political Bureau of the Communist Party of China (CPC) Central Committee held a meeting on Thursday to analyze...

CGTN: Why has China’s nature reserve network proved invaluable?

BEIJING, Sept. 28, 2024 /PRNewswire/ — Summer is the busiest season at Qinghai Lake, the largest saline lake in China. Birds feed and nurture their young,...

Frost & Sullivan Released Report: “2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends”

SHANGHAI, Sept. 28, 2024 /PRNewswire/ — Frost & Sullivan released the “2024 Blue Book on Chinese Biopharmaceuticals Going Global: Current Status and Trends” which focus on...

Natural Alternatives International, Inc. Announces Fiscal 2024 Q4 and YTD Results

CARLSBAD, Calif., Sept. 27, 2024 (GLOBE NEWSWIRE) — Natural Alternatives International, Inc. (“NAI”) (Nasdaq: NAII), a leading formulator, manufacturer, and marketer of customized nutritional supplements,...

BridgeBio Shares Recurrent Event Analysis of ATTRibute-CM, Demonstrating a 42% Reduction by Acoramidis on the Composite Endpoint of All-Cause Mortality and Recurrent Cardiovascular-related Hospitalization Events

– Acoramidis treatment led to a highly significant reduction in all-cause mortality (ACM) and recurrent cardiovascular-related hospitalizations (CVH) at Month 30 compared with placebo –...

Daxor Corporation Streamlines Regulatory Strategy for Groundbreaking Diagnostic Device

Company to Focus on 510(k) Approval Path, Accelerating Time-to-Market Oak Ridge, TN, Sept. 27, 2024 (GLOBE NEWSWIRE) — Daxor Corporation (NASDAQ: DXR), the global leader...

CARVYKTI® ▼ (ciltacabtagene autoleucel; cilta-cel) is the first cell therapy to significantly extend overall survival versus standard therapies for patients with multiple myeloma as early as second line

45 percent reduction in risk of death achieved with cilta-cel versus standard therapies after three-year follow-up in landmark CARTITUDE-4 study1 Data featured in a late-breaking...

CARVYKTI® is the First and Only Cell Therapy to Significantly Extend Overall Survival Compared to Standard of Care in Patients with Multiple Myeloma as Early as Second Line

Landmark CARTITUDE-4 study results show CARVYKTI® reduced the risk of death by 45 percent after three-year follow-up Late-breaking data featured in an oral presentation at...

A New Chapter for Fashionable, Modern Moms: Momcozy Reveals Latest Innovations at NYFW

New York, NY, Sept. 27, 2024 (GLOBE NEWSWIRE) — In the glamorous whirlwind of New York Fashion Week (NYFW), Momcozy unveiled a groundbreaking addition to...